Lexicon Pharmaceuticals, Inc. (LXRX) is a Biotechnology company in the Healthcare sector, currently trading at $1.86. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is LXRX = $6 (+222.6% upside).
Valuation: LXRX trades at a trailing Price-to-Earnings (P/E) of -12.5 (S&P 500 average ~25).
Financials: revenue is $50M, +1102.6%/yr average growth. Net income is $50M (loss), growing at -3.3%/yr. Net profit margin is -101.1% (negative). Gross margin is 99.4% (+306.6 pp trend).
Balance sheet: total debt is $62M against $108M equity (Debt-to-Equity (D/E) ratio 0.58, moderate). Current ratio is 4.88 (strong liquidity). Debt-to-assets is 33.6%. Total assets: $185M.
Analyst outlook: 5 / 14 analysts rate LXRX as buy (36%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 56/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
